SG10201912912QA - Production of oversized adeno-associated vectors - Google Patents
Production of oversized adeno-associated vectorsInfo
- Publication number
- SG10201912912QA SG10201912912QA SG10201912912QA SG10201912912QA SG10201912912QA SG 10201912912Q A SG10201912912Q A SG 10201912912QA SG 10201912912Q A SG10201912912Q A SG 10201912912QA SG 10201912912Q A SG10201912912Q A SG 10201912912QA SG 10201912912Q A SG10201912912Q A SG 10201912912QA
- Authority
- SG
- Singapore
- Prior art keywords
- oversized
- adeno
- production
- associated vectors
- vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144862P | 2015-04-08 | 2015-04-08 | |
| US201562220067P | 2015-09-17 | 2015-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912912QA true SG10201912912QA (en) | 2020-02-27 |
Family
ID=56943906
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909381W SG10201909381WA (en) | 2015-04-08 | 2016-04-07 | Production of oversized adeno-associated vectors |
| SG11201708203UA SG11201708203UA (en) | 2015-04-08 | 2016-04-07 | Production of oversized adeno-associated vectors |
| SG10201912912QA SG10201912912QA (en) | 2015-04-08 | 2016-04-07 | Production of oversized adeno-associated vectors |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909381W SG10201909381WA (en) | 2015-04-08 | 2016-04-07 | Production of oversized adeno-associated vectors |
| SG11201708203UA SG11201708203UA (en) | 2015-04-08 | 2016-04-07 | Production of oversized adeno-associated vectors |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10815497B2 (en) |
| EP (2) | EP3280799B1 (en) |
| JP (3) | JP6878299B2 (en) |
| KR (1) | KR20250126875A (en) |
| CN (1) | CN107864657A (en) |
| AU (3) | AU2016245806A1 (en) |
| BR (1) | BR112017021505A2 (en) |
| CA (1) | CA2982123A1 (en) |
| CL (1) | CL2017002537A1 (en) |
| CO (1) | CO2017011344A2 (en) |
| CR (1) | CR20170505A (en) |
| DK (1) | DK3280799T3 (en) |
| EA (1) | EA201792236A1 (en) |
| EC (1) | ECSP17074016A (en) |
| ES (1) | ES3008382T3 (en) |
| GT (1) | GT201700214A (en) |
| HU (1) | HUE069779T2 (en) |
| IL (3) | IL294965A (en) |
| MX (1) | MX2017012935A (en) |
| PE (1) | PE20171800A1 (en) |
| PH (1) | PH12017501836A1 (en) |
| PL (1) | PL3280799T3 (en) |
| SG (3) | SG10201909381WA (en) |
| TN (1) | TN2017000431A1 (en) |
| TW (1) | TWI707951B (en) |
| UY (1) | UY36611A (en) |
| WO (1) | WO2016164609A2 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2956477B2 (en) | 2013-02-15 | 2024-01-24 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| TWI707951B (en) * | 2015-04-08 | 2020-10-21 | 美商健臻公司 | Production of oversized adeno-associated vectors |
| RU2742352C2 (en) | 2015-09-24 | 2021-02-05 | Байомарин Фармасьютикал Инк. | Vectors of fviii factor based on adeno-associated viruses, corresponding virus particles and therapeutic compositions containing them |
| CN116218863A (en) | 2016-02-01 | 2023-06-06 | 比奥贝拉蒂治疗公司 | Optimized Factor VIII Gene |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| MX2018014154A (en) | 2016-05-18 | 2019-05-06 | Voyager Therapeutics Inc | MODULATING POLINUCLEOTIDES. |
| KR102427379B1 (en) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | Compositions and methods for treating Huntington's disease |
| EP3506817A4 (en) | 2016-08-30 | 2020-07-22 | The Regents of The University of California | METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM |
| WO2018154096A1 (en) | 2017-02-24 | 2018-08-30 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| MX2019013172A (en) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease. |
| MA49153A (en) * | 2017-05-19 | 2021-03-24 | Encoded Therapeutics Inc | HIGH ACTIVITY REGULATORY ELEMENTS |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| AU2018311069A1 (en) | 2017-08-03 | 2020-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| KR20250040746A (en) | 2017-08-09 | 2025-03-24 | 바이오버라티브 테라퓨틱스 인크. | Nucleic acid molecules and uses thereof |
| MX2020003042A (en) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery. |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| EP4124658A3 (en) | 2017-10-16 | 2023-04-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| CA3083765A1 (en) | 2017-12-01 | 2019-06-06 | Encoded Therapeutics, Inc. | Engineered dna binding proteins |
| MX2020012077A (en) | 2018-05-15 | 2021-03-09 | Voyager Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE. |
| CA3106838A1 (en) * | 2018-07-20 | 2020-01-23 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| US12364774B2 (en) | 2018-08-09 | 2025-07-22 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| JP2022504740A (en) * | 2018-10-12 | 2022-01-13 | ジェンザイム・コーポレーション | Generation of improved human PAHs for the treatment of severe PKU by gene replacement therapy directed to the liver |
| US20220349017A1 (en) * | 2019-08-29 | 2022-11-03 | Siemens Healthcare Diagnostics Inc. | Reagents and methods for detecting aav shedding |
| JP2022549932A (en) | 2019-09-30 | 2022-11-29 | バイオベラティブ セラピューティクス インコーポレイテッド | Lentiviral vector preparation |
| CN111218446B (en) * | 2019-12-25 | 2023-03-28 | 劲帆生物医药科技（武汉）有限公司 | Liver specificity promoter and application thereof |
| IL296509A (en) * | 2020-03-16 | 2022-11-01 | Univ North Carolina Chapel Hill | Preparations and methods for selective detection of tumor-derived viral DNA |
| BR112022026127A2 (en) | 2020-06-24 | 2023-01-17 | Bioverativ Therapeutics Inc | METHODS FOR REMOVING FREE FACTOR VIII FROM LENTIVIRAL VECTOR PREPARATIONS MODIFIED TO EXPRESS SUCH PROTEIN |
| AU2021319208A1 (en) | 2020-07-30 | 2023-03-02 | Shape Therapeutics Inc. | Stable cell lines for inducible production of rAAV virions |
| IL300445A (en) | 2020-08-23 | 2023-04-01 | Bioverativ Therapeutics Inc | Modified baculovirus system for improved production of closed-ended dna (cedna) |
| IL310963A (en) | 2021-08-23 | 2024-04-01 | Bioverativ Therapeutics Inc | Closed-end dna production with inverted terminal repeat sequences |
| JP2024534123A (en) | 2021-08-23 | 2024-09-18 | バイオベラティブ セラピューティクス インコーポレイテッド | Baculovirus Expression System |
| AU2022332276A1 (en) | 2021-08-23 | 2024-04-04 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| EP4408874A1 (en) | 2021-09-30 | 2024-08-07 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| AR132545A1 (en) * | 2023-04-26 | 2025-07-16 | Sanofi Sa | HOST CELL LINES AND METHODS FOR IDENTIFYING AND USING SUCH HOST CELL LINES |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| JP4827353B2 (en) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | Increased expression of single-stranded heterologous nucleotide sequences from recombinant viral vectors by designing sequences to form intrastrand base pairs |
| WO2001027303A1 (en) | 1999-10-12 | 2001-04-19 | The University Of North Carolina At Chapel Hill | Adeno-associated virus vectors encoding factor viii and methods of using the same |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| MX359371B (en) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby. |
| US20040092008A1 (en) * | 2002-11-12 | 2004-05-13 | Snyder Richard O. | Recombinant AAV vectors for gene therapy of hemophilia A |
| WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
| WO2004113494A2 (en) | 2003-05-21 | 2004-12-29 | Avigen, Inc. | Methods for producing preparations of recombinant aav virions substantially free of empty capsids |
| WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
| RS57784B1 (en) | 2009-06-16 | 2018-12-31 | Genzyme Corp | Improved methods for purification of recombinant aav vectors |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| WO2012112832A1 (en) | 2011-02-17 | 2012-08-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
| EP2911687B1 (en) * | 2012-10-26 | 2019-02-13 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
| SI3044231T1 (en) * | 2013-09-12 | 2020-12-31 | Biomarin Pharmaceutical Inc. | Aav vectors comprising a gene encoding factor viii |
| CN114231563B (en) | 2014-05-02 | 2024-08-16 | 建新公司 | AAV vectors for retinal and CNS gene therapy |
| HUE057272T2 (en) | 2015-02-10 | 2022-04-28 | Genzyme Corp | Increased uptake of virus particles into the striped body and cerebral cortex |
| TWI707951B (en) * | 2015-04-08 | 2020-10-21 | 美商健臻公司 | Production of oversized adeno-associated vectors |
-
2016
- 2016-04-06 TW TW105110751A patent/TWI707951B/en active
- 2016-04-07 IL IL294965A patent/IL294965A/en unknown
- 2016-04-07 CA CA2982123A patent/CA2982123A1/en active Pending
- 2016-04-07 CN CN201680033119.6A patent/CN107864657A/en active Pending
- 2016-04-07 PE PE2017001997A patent/PE20171800A1/en unknown
- 2016-04-07 EA EA201792236A patent/EA201792236A1/en unknown
- 2016-04-07 JP JP2017553005A patent/JP6878299B2/en active Active
- 2016-04-07 SG SG10201909381W patent/SG10201909381WA/en unknown
- 2016-04-07 SG SG11201708203UA patent/SG11201708203UA/en unknown
- 2016-04-07 WO PCT/US2016/026486 patent/WO2016164609A2/en active Application Filing
- 2016-04-07 SG SG10201912912QA patent/SG10201912912QA/en unknown
- 2016-04-07 EP EP16767050.4A patent/EP3280799B1/en active Active
- 2016-04-07 TN TNP/2017/000431A patent/TN2017000431A1/en unknown
- 2016-04-07 DK DK16767050.4T patent/DK3280799T3/en active
- 2016-04-07 ES ES16767050T patent/ES3008382T3/en active Active
- 2016-04-07 IL IL283291A patent/IL283291B/en unknown
- 2016-04-07 HU HUE16767050A patent/HUE069779T2/en unknown
- 2016-04-07 KR KR1020257027291A patent/KR20250126875A/en active Pending
- 2016-04-07 BR BR112017021505A patent/BR112017021505A2/en not_active Application Discontinuation
- 2016-04-07 PL PL16767050.4T patent/PL3280799T3/en unknown
- 2016-04-07 EP EP24207442.5A patent/EP4512429A3/en active Pending
- 2016-04-07 CR CR20170505A patent/CR20170505A/en unknown
- 2016-04-07 US US15/565,020 patent/US10815497B2/en active Active
- 2016-04-07 MX MX2017012935A patent/MX2017012935A/en unknown
- 2016-04-07 AU AU2016245806A patent/AU2016245806A1/en not_active Abandoned
- 2016-04-08 UY UY0001036611A patent/UY36611A/en not_active Application Discontinuation
-
2017
- 2017-10-06 PH PH12017501836A patent/PH12017501836A1/en unknown
- 2017-10-06 GT GT201700214A patent/GT201700214A/en unknown
- 2017-10-06 CL CL2017002537A patent/CL2017002537A1/en unknown
- 2017-10-08 IL IL254933A patent/IL254933B/en active IP Right Grant
- 2017-11-03 CO CONC2017/0011344A patent/CO2017011344A2/en unknown
- 2017-11-08 EC ECIEPI201774016A patent/ECSP17074016A/en unknown
-
2021
- 2021-04-28 JP JP2021075526A patent/JP2021118724A/en not_active Withdrawn
-
2022
- 2022-06-07 AU AU2022203942A patent/AU2022203942B2/en active Active
-
2023
- 2023-06-14 JP JP2023097370A patent/JP2023116678A/en active Pending
-
2024
- 2024-03-12 AU AU2024201619A patent/AU2024201619A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283291A (en) | Production of oversized adeno-associated vectors | |
| ZA201800029B (en) | Microbiome-compatible cosmetics | |
| HUE050747T2 (en) | Piece of luggage | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| SG10201601042PA (en) | Production of ester mixtures | |
| GB201508727D0 (en) | Polyurethane | |
| GB201502721D0 (en) | Product | |
| GB201509578D0 (en) | Vectors | |
| PL3283506T3 (en) | Process of manufacture of annexin v | |
| GB201518792D0 (en) | Production of proteins | |
| GB201521751D0 (en) | Novel uses | |
| GB2561109B (en) | Transition structure | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| GB201511225D0 (en) | Novel structure | |
| GB201506757D0 (en) | Cosmetic | |
| GB201516363D0 (en) | Enclosed Space | |
| IL253635A0 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| GB201505800D0 (en) | Motion arrangement | |
| GB201509881D0 (en) | Complementary vectors | |
| ZA201707704B (en) | Production of vcl4 | |
| PL3257657T3 (en) | Anti-spillage structure | |
| GB201601286D0 (en) | Multi-eptopic construct | |
| PL3497407T3 (en) | Monitoring relative motion of two elements | |
| GB201601249D0 (en) | Production of manool | |
| GB201521180D0 (en) | Encapsulated moluscicide |